english.prescrire.org > Prescrire International > N°192 - April 2018

n°192

April 2018

Issue Contents
Editorial

Free  "No" to bulk bottles of loose tablets or capsules!

p.87

Marketing Authorisations


Sofosbuvir + velpatasvir (Epclusa°) in chronic hepa­titis C

p.89-92
An advance in HCV genotype 2 infection

Inset. Gilead and the European Medicines Agency are hiding adverse effects from patients

p.92

Elbasvir + grazoprevir (Zepatier°) and hepa­titis C

p.92
No comparison with first-choice treatments

Ixekizumab (Taltz°) and plaque psoriasis

p.93-94
Effects similar to secukinumab, but no demonstrated ­advantages

Oral weekly methotrexate (Novatrex°): in blister packs

p.95

INN Common stem: -pril

p.96

INN Common stem: -relix

p.96

Adverse Effects


InfanrixHexa°: errors in reconstituting the vaccine

p.97

Proton pump inhibitors: listeriosis

p.97

Amphotericin B: confusion between pharmaceutical formulations

p.98

Donepezil: hypersexuality

p.98

Ambroxol, bromhexine: Stevens-Johnson syndrome and toxic epidermal necrolysis

p.99

Valaciclovir, aciclovir: renal failure and neurotoxicity

p.99

Brimonidine for topical application: episodes of bradycardia and hypotension

p.100

Benzodiazepines: pneumonia

p.100

Loratadine and desloratadine: weight gain

p.101

Drug-induced blepharospasm: antiepileptics, psychotropics

p.101

Reviews


Treating intermittent claudication

p.102-106
First encourage patients to follow a walking exercise ­programme

Outlook


Free  Towards better patient care: drugs to avoid in 2018

p.107-109

Free  Inset. Notable changes in the 2018 update

p.109

Free  Drugs in 2017: a brief review

p.110-111

Masthead


Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe